Last updated: February 24, 2026
What is NDC 00536-1306?
NDC 00536-1306 refers to Xyrem (sodium oxybate), a medication approved for the treatment of narcolepsy with cataplexy and excessive daytime sleepiness. It contains a highly regulated spectral of the gamma-hydroxybutyrate (GHB) class.
Market Overview
Market Size and Growth Drivers
- The global narcolepsy treatment market was valued at approximately $1.2 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 4.2% through 2030 [1].
- Xyrem accounts for an estimated 85% of the prescribed narcolepsy drug market due to its efficacy and FDA approval status.
- Growing awareness of sleep disorders, expanded diagnosis rates, and recent FDA approvals for pediatric use contribute to increased demand.
Competitive Landscape
- Major competitors: Sunosi (sulpiride), Wakix (pitolisant), and off-label stimulants.
- Xyrem’s patent expiry was in 2015; however, the drug remains proprietary due to strict production controls and abuse deterrence mechanisms.
- Market share dominance remains with Jazz Pharmaceuticals, which owns Xyrem.
Regulatory Environment
- The drug is classified as a Schedule III controlled substance.
- Ongoing DEA restrictions affect distribution and prescribing practices, limiting market penetration generally.
Distribution Channels
- Specialty pharmacies controlled by Jazz Pharmaceuticals.
- Prescriptions tend to be high-cost, with rigorous monitoring and patient requirements.
Price Trends and Projections
Current Pricing
- The average wholesale price (AWP) per 30 mL unit is approximately $600.
- Typical annual treatment cost ranges between $30,000 and $45,000, depending on dosage and patient compliance [2].
Pricing Drivers
- Strict regulatory controls and manufacturing costs sustain high prices.
- Limited generic competition due to regulatory barriers reduces downward pricing pressure.
- The abuse-deterrent formulation and distribution restrictions preserve pricing levels.
Price Forecasts
- Short term (1–3 years): Prices are expected to remain steady due to regulatory restrictions.
- Medium term (3–5 years): Potential slight declines if regulatory modifications or increased generic manufacturing occur, but unlikely to fall below $25,000 annually.
- Long term (5+ years): Prices may decrease marginally as patents expire or with technological advancements in formulation, but stabilization is possible due to high barriers to entry.
Future Market and Price Dynamics
Impact of Patent and Market Entry
- No generic version is currently available; patent protection may have expired or is under patent extensions.
- Patent expiration expected or already occurred in 2015; however, manufacturing barriers prevent immediate generic entry.
Regulatory and Policy Influence
- DEA scheduling policies and distribution controls limit the rapid entry of generics.
- Potential legislative reforms could influence drug pricing or approval processes, but no specific policy changes are imminent.
Emerging Alternatives
- New drugs in clinical trials may influence the market, but none currently pose an immediate threat.
Summary Table: Price and Market Projections
| Time Frame |
Price Trend |
Key Drivers |
| 0–3 years |
Stable |
Regulatory controls, distribution restrictions |
| 3–5 years |
Slight decline |
Potential biosimilar or generic approval, market maturity |
| 5+ years |
Marginal decrease or stabilization |
Patent expirations, technological improvements |
Key Takeaways
- NDC 00536-1306 (Xyrem) dominates the narcolepsy market with high and stable pricing due to regulatory and manufacturing barriers.
- The market is expected to maintain current price levels for at least the next three years.
- Price reductions remain unlikely unless significant regulatory or patent changes occur.
- The growth outlook remains positive, driven by increased diagnosis and treatment awareness.
FAQs
1. Is a generic version of Xyrem available?
No. Complex manufacturing and strict controls prevent generic entry despite patent expiration.
2. How does DEA regulation impact Xyrem's market?
DEA schedules Xyrem as a Schedule III drug, imposing limits on distribution and prescribing, which constrains market expansion.
3. What factors could lower Xyrem prices in the future?
Patent expirations combined with regulatory changes that facilitate generic manufacturing could lead to price reductions.
4. What is the primary cost to patients?
Treatment costs typically range from $30,000 to $45,000 annually, influenced by dosage and compliance.
5. Are there emerging treatments that threaten Xyrem’s market share?
No immediate competitors are clinical-approved treatments with similar efficacy, but ongoing research may change this landscape.
References
[1] Market Research Future. (2022). Narcolepsy treatment market.
[2] IQVIA Institute. (2022). Drug price data and analysis.
[3] U.S. FDA. (2015). Approvals and patent details for Xyrem.
